TNF receptor and steroid hormone in a combined therapy

Details TNF receptor and steroid hormone in a combined therapy TNF receptor and steroid hormone in a combined therapy

2006-03-14

2006-03-14

Murphy, Joseph (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S171000, C514S170000, C514S012200, C514S169000, C530S350000

Reexamination Certificate

active

07012060

ABSTRACT:
The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified treatment.In particular, it relates to the use of TBP-1 together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.

REFERENCES:
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 6054487 (2000-04-01), Sekut et al.
patent: 6225300 (2001-05-01), Boe et al.
patent: 92/512528 (1992-11-01), None
patent: EP 308 378 (1989-03-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 95/03827 (1995-02-01), None
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc., pp. 126-128 and 228-234.
Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437-57.
The Merck Manual of Diagnosis and Therapy, Beers and Berkow, eds. Merck Research Laboratories, Whitehouse Station, N.J 1999, pp. 1061-1063.
The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Robert Berkow, M.D.,Editor-in-Chief, 1992, Merck & Co., Inc., New Jersey, pp. 71, 2664 and 2780.
H.D. Danenberg, et al., “Dehydroepiandrosterone Protects Mice from Endotoxin Toxicity and Reduces Tumor Necrosis Factor Production”,—Antimicrob Agents Chemother, vol. 36, No. 10, 1992, pp. 2275-2279.
R.F. Van Vollenhoven et al., “In Patients With Systematic Lupus Erythematosus, treatment with Oral Dehydroepiandrosterone Restores Abnormally Low In Vito Production of IL-2, IL-6 and TNF-alpha”,Arthritis and Rheumatism, vol. 37, No. 9, suppl., 1994, p. 407.
J.Y. Yang et al., “Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA”, vol. 9, No. 8, 1993, pp. 747-754.
M. Cutolo et al., “Immunomodulatory Mechanisms Mediated by Sex Hormones in Rheumatoid Arthritis”,Annals of the New York Academy of Sciences, Basis for Cancer Management. Conference on Propedeutics to Cancer Management, France, Italy, Apr. 1-6, 1995, vol. 784, 1996, pp. 237-251.
F.C. Kull, “Reduction in Tumor Necrosis Factor Receptor Affinity and Cytotoxicity by Glucocotticoids”,Biochem., Biophys. Res. Commun., vol. 153, No. 1, 1988, pp. 402-409.
W.P. Arend et al., “Inhibition of the Production and Effects of Interleukin-1 and Tumor Necrosis Factor Alpha in Rheumatoid Arthritis”,Arthritis Rheum., vol. 38, No. 2, Feb. 1995, pp. 151-160.
E. Girardin et al., “Cytokines et antagonists dans le choc septique”,Schweiz. Med. Wschr., vol. 123, No. 11, 1993, pp. 480-491.
S.M. Opal et al., “Tumor Necrosis Factor Receptor-Fc Fusion Protein (sTNFR:Fc) in the Treatment of Experimental Pseudomonas Spesis”,Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, vol. 33, No. 0, 1993, p. 378.
E. Tartour et al., “Anti-Cytokines: Promising Tools for Diagnosis and Immunotherapy”,Biomed Pharmacother, vol. 48, No. 10, 1994, pp. 417-424.
D. Russel et al., “Synergistic Protection Against Lethal Exdotoxemia by Treatment with Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein”,Lymphokine and Cytokine Research, vol. 12, No. 5, 1993, p. 377.
Stedman's Medical Dictionary,26 Ed. Williams & Wilkins, Baltimore, pp. 1608-1609, 1995.

Affiliated with

Also associated with

Rating

TNF receptor and steroid hormone in a combined therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TNF receptor and steroid hormone in a combined therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF receptor and steroid hormone in a combined therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3612691